`
`HOME ADDRESS
`54 Hilltop Drive
`Madison, CT 06443
`Email: rogershoward@sbcglobal.net
`Practice Website: advanceddermatologyct.com
`
` Tel: (860)859-2262
`Fax: (860)859-9819
`Cell: (860)917-8842
`
`MEDICAL EXPERIENCE
`Guilford, CT
`2017-Pres. Shoreline Mohs Surgery
`Private Practice Dermatologic Surgery (Owner)
`
`Norwich, CT
`2004-Pres. Advanced Dermatology LLC
`Private Practice General and Surgical Dermatology (Owner)
`
`Norwich, CT
`2000-2004 Chelsea Clinic Surgery
`Private Practice General and Dermatologic Surgery
`
`EDUCATION
`Cincinnati, OH
`2007-2008 Skin Cancer Center
`Surgical Fellowship in Mohs Micrographic Surgery
`
`1997-2000 Washington University School of Medicine St. Louis, MO
`Dermatology Residency, Chief Resident
`
`1996-1997 University of Maryland Hospital
`Internship in Internal Medicine
`
`Baltimore, MD
`
`1989-1996 Washington University School of Medicine St. Louis, MO
`M.D.-Ph.D. Combined Degree Program
`Ph.D. in Immunology
`
`1
`
`
`
`1985-1989 Harvard University
`B.S. in Biology, Magna Cum Laude
`
`Cambridge, MA
`
`CERTIFICATIONS
`2000, 2010 Board Certified American Board of Dermatology
`2009
`Fellow member American College of Mohs Micrographic
`Surgery
`
`MEDICAL ASSOCIATIONS AND POSITIONS
`Fellow member American Academy of Dermatology, Fellow member
`American College of Mohs Surgery, American Society of Mohs Surgery,
`American Society of Dermatologic Surgery, Masters Dermatologic
`Association, American Medical Association, Connecticut Dermatology
`Society, American Dermatologic Association
`
`NATIONAL ASSOCIATION LEADERSHIP
`American Academy of Dermatology
`-Chair, Patient Access and Payer Relations Committee 2014-2018, advisor
`2018-present
`-Chair, Physician Payment Reform Workgroup 2011-2012
`-Board of Directors, SkinPAC Political Action Committee 2018-present
`-Coding and Reimbursement Committee 2019-present
`-Performance Measures Committee 2013-2018
`-Healthcare Finance Committee 2011-2014
`-Workgroup on Innovation in Payment and Delivery 2013-present, chair
`2020-present
`-Expert Resource Group of Quality and Patient Safety 2013-2016
`
`2
`
`
`
`-Private Sector Advocacy Taskforce 2012-2014
`-Deputy Chair, Resource Based Relative Value System Committee 2015-
`present
`-Chair, Phototherapy Documentation Workgroup 2016-2017
`-Skin Cancer Measure Development Workgroup 2014-2016
`-Patient Reported Outcomes Measure Development Workgroup 2016-2018
`-Governmental Affairs and Healthcare Policy Council 2017-2019
`-Performance Measures Needs Assessment Workgroup 2017-2018
`-Immunohistochemistry Appropriate Use Workgroup 2019
`-Evaluation and Management Member Education Workgroup 2020-present
`-Question of the Week Coding Workgroup 2019-2020
`-Connecticut State Leader Legislative Conference 2020
`-Step Therapy Workgroup 2020
`-Task Force on E/M Coding Revision Impact 2021
`American College of Mohs Surgery
`-Vice President 2021
`-Secretary Treasurer 2020-2021
`-ACMS Board of Directors 2016-2019
`-Chair, AMCS Private Sector Task Force 2013-pres
`- Scientific Program Committee Cochair 2012, Chair 2013, Ex Officio 2014,
`Member 2020-present
`- ACMS representative to AMA Relative Value Update Committee (RUC)
`2014 –pres
`-Chair, ACMS Finance Committee 2020-2021
`- ACMS National Registry and Outcomes Committee, Vice Chair 2013-
`2016, Chair 2017-2019, advisor 2020-present
`- Chair of ACMS Mohs Log Subcommittee 2013-2015
`
`3
`
`
`
`-ACMS representative to Centers for Medicare and Medicaid Services
`MACRA Resource Use Measure Clinical Committee 2016- 2020
`
`-Chair of Oncology Subcommittee of Centers for Medicare and Medicaid
`Services Acumen MACRA Resource Use Measure Clinical Committee 2018
`-Chair of Dermatologic Care Subcommittee of Centers for Medicare and
`Medicaid Services Acumen MACRA Resource Use Measure Clinical
`Committee 2019-2021
`-Public Policy Committee 2012-pres
`-Alliance for Specialty Medicine (ASM), ACMS Representative 2014-pres
`- ACMS Membership Committee 2012-2014, 2020-2021
`American Society of Dermatologic Surgery
`-ASDS State Advocacy Taskforce 2020
`-ASDS Task Force on Value Analysis 2016-pres
`-ASDS Alternative Payment Model Workgroup 2014—2015
`Centers for Medicare and Medicaid Services
`Dermatology representative to Carrier Advisory Committee for Medicare
`Administrative Contractor, National Government Services 2019-present
`
`Council of Medical Specialty Societies
`-Representative to the Ambulatory Quality Alliance 2012-2013
`Congressional Testimony
`-Testified before Congressional Small Business Committee representing
`AADA regarding the burden of step therapy and prior authorization 2019
`
`INDUSTRY POSITIONS
`-Humana Inc., Physician Provider Collaborative Committee, 2013-2016
`-Case and policy reviewer for Medical Review Institute of America
`
`4
`
`
`
`COMMUNITY SERVICE
`2000-pres. Organized 53 community skin cancer screening programs in
` conjunction with William W. Backus Hospital
`2002-pres. Speaker for community education program in conjunction with
`William W. Backus Hospital education department
`
`CLINICAL RESEARCH
`2001-2003 Phase 3 study site for efalizumab efficacy in psoriasis
`(Genentech)
`2005 Trial study site for community based efficacy study of
`adapalene for acne (Galderma)
`2005-2008. ATLAS study on long term safety of alefacept for psoriasis
`(Biogen-Idec)
`
`HONORS
`2017
`
`American Academy of Dermatology – Presidential Citation for
`service in insurer and regulatory advocacy
`American Academy of Dermatology – Presidential Citation for
`service as advisor to AMA RUC
`American Academy of Dermatology – Performance Measures
`Pioneer Award
`Distinguished Service Award, American College of Mohs
`Surgery
`1999-2000 Chief Resident, Dermatology Residency, Washington
`University School of Medicine
`1996 Henry Yalem Prize in Dermatology, awarded for outstanding
`
`2017
`
`2017
`
`2014
`
`5
`
`
`
`work in Dermatology
`1995 Spencer T. Olin Fellowship in recognition of superior
`achievement in biomedical research
`1989-1995 Swazey Scholar for Academic Distinction in Medical Pursuits
`
`Languages – English, Spanish
`
`PUBLICATIONS
`1. Burd PR, Rogers HW, Gordon JR, Martin CA, Jayaraman S,
`Wilson S, Dvorak AM, Galli SJ, Dorf ME: Interleukin 3-
`dependent and independent mast cells stimulated with IgE
`and antigen express multiple cytokines. J Exp Med
`170:245-257, 1989.
`2. Rogers HW, Sheehan KCF, BruntLM, DowerSK, Unanue
`ER, Schreiber RD: Interleudin-1 participates in the
`development of anti-Listeria responses in normal and SCID
`mice. Proc Natl Acad Sci USA 89:1011-1015, 1992.
`3. Beckerman KP, Rogers HW, Corbett JA, Schreiber RD,
`McDaniel ML, Unanue ER: Release of nitric oxide during
`the T cell independent pathway of macrophage activation.
`Its roles in resistance to Listeria monocytogenes. J Immunol
`150: 888-895, 1993
`4. Rogers HW, Unanue ER: Neutrophils are involved in acute,
`nonspecific resistance to Listeria monocytogenes in mice.
`Infect and Immun 61:5090-5096, 1993.
`5. Rogers HW, Tripp CS, Schreiber RD, Unanue ER:
`Endogenous IL-1 is required for neutrophil recruitment and
`
`6
`
`
`
`macrophage activation during murine Listeriosis. J Immunol
`152:2093-2101, 1994.
`6. Rogers HW, Unanue ER: Different stages in the natural and
`acquired resistance to an intracellular pathogen. The
`Immunologist 3:152-156, 1995.
`7. Rogers HW, Callery M, Unanue ER: Listeria induces
`hepatocyte apoptosis: implications for the role of neutrophils
`in Listeria resistance. J Immunol 156:679-684, 1996.
`
`8. Coldiron BM, Dinehart S, Rogers HW: Sentinel lymph
`node biopsy and completion lymph node dissection for
`malignant melanoma are not standard of care. Clin.
`Dermatol. 2009.
`
`9. Rogers HW, Coldiron BM: A Relative Value Unit Based
`Cost Comparison of Treatment Modalities for Non-
`Melanoma Skin Cancer. J Am Acad Dermatol. 2009
`Jul;61(1):96-103.
`10.Rogers HW, Coldiron BM: Sentinel node biopsy not
` standard of care for melanoma. J Am Acad Dermatol. 2011
` Feb;64(2):441.
`11.Rogers HW, Coldiron BM: Unconflicted. J Am Acad
` Dermatol. 2011 Feb;64(2):437-8.
`12.Rogers HW, Weinstock MA, Harris AR, Hinckley MR,
` Feldman SR, Fleischer AB, Coldiron BM: Incidence
` estimate of nonmelanoma skin cancer in the United States,
` 2006. Arch Dermatol. 2010 Mar;146(3):283-7.
`13. Rogers HW, Coldiron BM. Analysis of skin cancer
` treatment and costs in the United States Medicare
`
`7
`
`
`
` population, 1996-2008. Dermatol Surg. 2013 Jan;39(1 Pt
` 1):35-42.
`14. Rogers HW, Coldiron BM, Dinehart SM, Hendi A, Hruza
` G, Fosko SW, Moody BR. Skin cancer treatment fee
` comparisons inaccurate. Dermatol Surg. 2012
` Dec;38(12):2038-9.
`15. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM.
` Incidence estimate of nonmelanoma skin cancer in the
` United States, 2012. Arch Dermatol. JAMA Dermatol.
` 2015 Oct;151(10):1081-6.
`16. Rogers HW. Is cryosurgery cost effective in the treatment
` of non-melanoma skin cancer? Dermatological
` Cryosurgery and Cryotherapy, Springer, New York, NY.
` 2016.
`17. Rogers HW. Is Mohs Surgery Cost-Effective versus
` Traditional Surgical Excision? Current Dermatology
` Reports: Volume 3, Issue 2 (2014), 91-97.
`18. Leitenberger JJ, Rogers HW, Chapman JC, Maher IA, Fox
` MC, Harmon CB, Bailey EC, Wisco OJ. Defining
` Recurrence of Non-Melanoma Skin Cancer after Mohs
` Micrographic Surgery: Report of the American College of
` Mohs Surgery Registry and Outcomes Committee. J Am
` Acad Dermatol. 2016 Nov;75(5):1022-1031.
`19. Rogers HW. One diagnosis and modifier -25: appropriate
` or audit target? Cutis. 2017 Mar;99(3):165-166.
`20. Rogers HW. Phototherapy coding in the time of biologics.
` Cutis. 2017 July;100(1):41-42.
`
`8
`
`
`
`21. Tolkachjov SN, Brodland DG, Coldiron BM, Fazio MJ,
`
`Hruza GJ, Roenigk RK, Rogers HW, Zitelli JA, Winchester
`
`DS, Harmon CB. Understanding Mohs Micrographic Surgery:
`
`A Review and Practical Guide for the Nondermatologist. Mayo
`
`Clin Proc. 2017 Aug;92(8):1261-1271.
`
`22. Rogers HW. Modifier -25 Victory, But the Battle Is Not
`
`Over. Cutis. 2018 June;101(6):409-410
`
`23. Rogers HW. Practice Expense–Only Codes: No Physician
`
`Work, No Sweat. Cutis. 2018 Nov;101(6):348-352
`
`24. Rogers HW, Beveridge M, Puente J, Wixson S, Loy B,
`
`Happe LE Incidence of non-melanoma skin cancer in the US
`
`population aged 65 years and older, 2014. J Am Acad
`
`Dermatol. J Am Acad Dermatol. 2021 Sep;85(3):741-743.
`
`25. Aizman L , Damavandy AA , Snider CK , Lukowiak TM ,
`
`Perz AM , Etzkorn JM , Beer J , Thuzar M Shin , Sobanko JF ,
`
`Giordano CN , Higgins HW, Fischer J, Brody RM , Rogers
`
`HW , Miller CJ. Incidence of and risk factors for neighboring
`
`synchronous skin cancers during Mohs micrographic surgery: A
`
`prospective cohort study J Am Acad Dermatol. 2021 Apr
`
`20;S0190-9622.
`
`9
`
`
`
`26. Rogers HW. Modifier -25 and the New 2021 E/M Codes:
`
`Documentation of Separate and Distinct Just Got Easier Cutis.
`
`2021 Sept.;108(03):131-132, 162
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`10
`
`